Abbott launches SimpleScreen CRC for Abbott Laboratories stock

Abbott Laboratories (ISIN US0028241000) launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test, on October 1, 2026, according to MarketBeat. The product, developed by Freenome and commercialized exclusively by Abbott, expands the company's colorectal cancer screening portfolio alongside Cologuard Plus.

Screening adds a new growth lever

SimpleScreen CRC is intended for average-risk adults aged 45 and older, and Medicare covers eligible Part B patients, MarketBeat reported on October 1, 2026. The launch gives Abbott another commercial channel in diagnostics while its medical-device operations remain the main earnings engine.

The Motley Fool reported on September 18, 2026, that Abbott's Medical Devices segment grew 8.40 percent on a comparable basis in the second quarter of 2026 and generated nearly USD 6.00 billion in sales. The segment's pace matters because faster-growing devices are carrying more of the company's earnings expansion.

Second-quarter figures set the bar

Abbott reported USD 12.59 billion in revenue for the second quarter of 2026, up 13.00 percent from the same quarter a year earlier, while earnings per share reached USD 1.31 versus a USD 1.28 consensus estimate, according to MarketBeat. The revenue comparison is the clearest operating measure behind the company's expanded diagnostics strategy.

MarketBeat said Abbott set third-quarter 2026 earnings-per-share guidance at USD 1.38 to USD 1.46 and full-year 2026 guidance at USD 5.45 to USD 5.60. The next test arrives before the market opens on October 21, 2026, when Abbott is scheduled to report third-quarter results.

Analyst support meets a valuation test

MarketBeat reported on October 1, 2026, that 27 ratings firms carried a Moderate Buy consensus, including 20 buy ratings, four holds and three strong-buy ratings. The average 12-month price target was USD 119.50, while the same report placed Abbott's market capitalization at USD 171.3 billion and its 12-month range at USD 81.97 to USD 135.45.

Abbott stock trades in Germany

Abbott Laboratories stock was trading at EUR 87.41 at Lang & Schwarz on October 1, 2026 at 10:33 a.m. CEST, plus 0.41 percent versus the prior close of EUR 87.05. The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.

More news and analyses on Abbott Laboratories stock